MAZE Q3 2024 Earnings — Maze Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

MAZEMaze Therapeutics, Inc.

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M

Gross Profit

$3M100.0% margin

Operating Income

-$24M-969.2% margin

Net Income

-$25M-990.1% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

-98.5%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$192M

Total Liabilities

$93M

Stockholders' Equity

$99M

Cash & Equivalents

$150M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$0	—
Gross Profit	$3M	$0	—
Operating Income	-$24M	-$25M	+4.0%
Net Income	-$25M	-$25M	-0.0%